Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Gap Down – Here’s Why

Swedish Orphan Biovitrum (OTCMKTS:BIOVF)’s share price gapped down before the market opened on Tuesday. The stock had previously closed at $48.1264, but opened at $42.80. Swedish Orphan Biovitrum shares last traded at $42.80, with a volume of 20,000 shares.

Analysts Set New Price Targets

Several research analysts recently commented on BIOVF shares. Pareto Securities lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th. Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

The stock has a fifty day simple moving average of $47.64 and a 200-day simple moving average of $46.24. The company has a market capitalization of $15.24 billion, a price-to-earnings ratio of 95.11 and a beta of 0.33. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.88 and a quick ratio of 0.55.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing treatments for rare diseases. Its activities center on conditions in hematology, immunology and specialty care, where patients often have limited treatment options.

Sobi’s portfolio includes therapies for hemophilia and other bleeding disorders, immune-mediated diseases, and rare inflammatory or hematologic conditions. Its products include Elocta and Alprolix for hemophilia, Doptelet for certain platelet disorders, Gamifant for primary hemophagocytic lymphohistiocytosis, and Aspaveli for paroxysmal nocturnal hemoglobinuria.